1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
MicroPort CardioFlow Medtech Corporation

MicroPort CardioFlow Medtech Corporation

2160.HK
MicroPort CardioFlow Medtech CorporationHK flagHong Kong Stock Exchange
1.15
HKD
+0.02
- -
565.52MMarket Cap
MicroPort CardioFlow Medtech Corporation
2160.HK
(Hong Kong Stock Exchange)

Recent

price

1.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.01
0.03
0.07
0.08
0.1
0.11
0.58
Revenue per Share
-0.02
-0.04
-0.13
-0.06
-0.14
-0.14
-0.01
-0.19
Basic EPS, GAAP
-0.04
-0.06
-0.05
-0.09
-0.07
-0.07
-0.08
-0.39
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.21
-0.28
-0.39
-0.54
-0.56
-2.85
Book Value per Share
0.02
-0.03
-0.19
0.96
0.79
0.65
0.6
1.16
Tangible Book Value per Share
473
473
473
466
473
473
468
98
Basic Weighted Avg Shares
- -
3
16
32
36
47
51
57
Sales/Revenue/Turnover
- -
-574.13
-178.36
-101.19
-132.21
-104.59
-44.16
-35.88
Operating Margin (%)
- -
2
4
7
11
10
12
14
Depreciation Expense
-9
-21
-61
-29
-66
-67
-7
-19
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-672.13
-383.02
-91.26
-181.02
-140.25
-13.68
-32.99
Profit Margin (%)
-6
-29
-109
382
304
261
173
225
Working Capital
2
2
1
14
9
6
2
209
LT Debt
40
19
-53
486
399
330
309
256
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-2,109.56
-652,601.64
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-215.61%
-17.09%
Free Cash Flow
- -
11.55%
2.18%
Net Income, GAAP
- -
31.71%
170.85%
Sales/Revenue/Turnover
- -
32.66%
12.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
47
2024
- -
- -
- -
- -
51
2025
- -
- -
- -
- -
57

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.14
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.19

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Vivos Therapeutics, Inc. (VVOS)
ShockWave Medical, Inc. (SWAV)
NuGen Medical Devices Inc. (NGMDF)
Profusa, Inc. Common Stock (PFSA)
HOB Biotech Group Corp.,Ltd (688656.SS)
Cue Health Inc. (HLTHQ)
Business
MicroPort CardioFlow Medtech Corporation (2160.HK), headquartered in Shanghai, China and founded in 2009, develops, manufactures and commercializes transcatheter and surgical medical devices focused on structural heart diseases including valvular heart conditions and left atrial appendage closure; its core products comprise the VitaFlow series transcatheter aortic valve implantation (TAVI) systems such as VitaFlow Liberty (the world's first electric retrievable TAVI system with EU CE-MDR certification in 2024), VitaFlow Liberty Flex and VitaFlow IV, Alwide balloon catheters including Alwide Plus, procedural accessories like Alpass Introducer Set and Angelguide super stiff guidewire, AnchorMan left atrial appendage closure (LAAC) systems, transcatheter mitral valve (TMV) and tricuspid valve (TTV) products in development, and surgical valves and accessories. The company serves physicians and patients through total solutions for structural heart treatments, with its TAVI products and accessories implanted in over 700 core hospitals across more than 20 countries and regions worldwide, treating over 10,000 patients; it operates primarily in China and internationally. Recent developments include the first commercial implantations of VitaFlow Liberty in Türkiye in 2025 highlighting its retrievability and efficiency, a strategic investment as largest shareholder in partner 4C Medical's US$175 million Series D financing in March 2025 to advance transcatheter mitral valve replacement, and a proposed US$680 million merger with MicroPort Cardiac Rhythm Management (a MicroPort Scientific subsidiary) announced in September 2025 to create a diversified global heart disease platform under Hong Kong Listing Rules Chapter 18A.